Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease

NCT03437720 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision to cancel TRIAL, not related to safety concern.

Conditions

Non-alcoholic Steatohepatitis
Type 2 Diabetes Mellitus

Interventions

DRUG: SAR425899
DRUG: Placebo

Sponsor

Sanofi